Company profile: Orchard Therapeutics
1.1 - Company Overview
Company description
- Provider of autologous ex vivo gene therapies for rare genetic diseases, including Libmeldy (EU-approved for MLD) and Strimvelis (EMA-approved for ADA-SCID), built on a hematopoietic stem cell gene therapy platform. Also conducts clinical trials, supports investigator-initiated research, and funds independent medical education on gene therapy.
Products and services
- HSC Gene Therapy Platform: Autologous ex vivo platform that modifies patients’ hematopoietic stem cells to treat genetic diseases, demonstrating sustained clinical benefit in over 150 patients across five areas
- Libmeldy: EU-approved gene therapy for Metachromatic Leukodystrophy that delivers a one-time treatment engineered to correct the underlying genetic cause in affected patients
- Strimvelis: EMA-approved autologous ex vivo gene therapy for ADA-SCID that employs the patient’s own genetically modified stem cells, the first therapy of its kind approved by the EMA
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Orchard Therapeutics
Genome Medical
HQ: United States
Website
- Description: Provider of telegenomics technology and services enabling access to genomic-based medicine, including telehealth genetic counseling; Test Plan for test review, authorization, ordering and personalized outreach; a Digital Risk Assessment module; Precision Insights strategic advisory; MCED testing facilitation with clinical action plans; and reproductive genetics counseling and testing.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Genome Medical company profile →
Solid Biosciences
HQ: United States
Website
- Description: Provider of gene therapy candidates and research focused on rare genetic diseases, including SGT-003 for Duchenne muscular dystrophy, SGT-501 for catecholaminergic polymorphic ventricular tachycardia, and AVB-401 for BAG3-mediated dilated cardiomyopathy.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Solid Biosciences company profile →
Cytox Group
HQ: United Kingdom
Website
- Description: Provider of a simple genetic based blood test for the assessment of risk and diagnosis of Alzheimer's Disease in the very early stages.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cytox Group company profile →
Inivata
HQ: United States
Website
- Description: Provider of clinical cancer genomics and liquid biopsy solutions using circulating tumor DNA (ctDNA) to improve testing and treatment. Offers assays and NGS profiles for lung and myeloid cancers, including InVisionFirst-Lung, NeoTYPE DNA & RNA - Lung, Neo Comprehensive - Myeloid Disorders, and an early-stage NSCLC panel, plus NeoSeek for biomarker cohort analysis and NeoAccess for streamlined test ordering.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Inivata company profile →
Microbiotica
HQ: United Kingdom
Website
- Description: Provider of human microbiome therapeutics and biomarkers, offering live bacterial therapeutics that engraft in the intestine; microbiome-based biomarkers for drug response, side-effects, or disease progression to stratify patients; a gut bacteria Culture Collection and proprietary Reference Genome Database; advanced microbiome bioinformatics and machine learning; and Personalised Bacterial Banks.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Microbiotica company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Orchard Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Orchard Therapeutics
2.2 - Growth funds investing in similar companies to Orchard Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Orchard Therapeutics
4.2 - Public trading comparable groups for Orchard Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →